Compare Gilead Sciences, Inc. (GILD) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs MasTec Inc — how do they compare? Gilead Sciences, Inc. trades at $135.26 (market cap $164.99B), while MasTec Inc trades at $273.94 (market cap $21.54B). The key difference: Gilead Sciences, Inc. is far larger — about 7.7× MasTec Inc's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| GILD | MTZ | |
|---|---|---|
Market Cap | $164.99B | $21.54B |
Sector | Health | Technology |
52-Week High | $155.80 | $437.51 |
52-Week Low | $110.56 | $172.51 |
Enterprise Value | $188.06B | $24.46B |
Dividend Yield | 2.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MasTec (MTZ) trades at $272.46, up 5.35% with strong YTD performance of 25.9%, outperforming the S&P 500. The stock shows bearish technical signals but maintains robust fundamentals with record Q2 2026 revenue of $4.37B and 40% EBITDA growth. Recent acquisition of The Superior Group for $1.65B expands critical infrastructure capabilities. The company raised 2026 guidance citing strong infrastructure demand and a record $21.4B backlog.
Despite technical weakness, MasTec's strong earnings momentum and 88.9% analyst buy rating with $447.91 price target suggest significant upside. Key risks include execution of large acquisitions and communications segment delays. The stock offers exposure to infrastructure growth trends but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
